Pfiz­er jumps in­to the heat­ed PhI­II race for new-wave JAK in­hibitors — but safe­ty frets loom large

Pfiz­er has racked up a pos­i­tive slate of Phase III da­ta for its an­ti-in­flam­ma­to­ry JAK1 in­hibitor abroc­i­tinib (PF-04965842), which the phar­ma gi­ant is hop­ing to …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER